Medium Term Outcomes of Transapical Aortic Valve Implantation: Results From the Italian Registry of Trans-Apical Aortic Valve Implantation

D’Onofrio, Augusto; Salizzoni, Stefano; Agrifoglio, Marco; Cota, Linda; Luzi, Giampaolo; Tartara, Paolo; Cresce, Giovanni Domenico; Aiello, Marco; Savini, Carlo; Cassese, Mauro; Cerillo, Alfredo Giuseppe; Punta, Giuseppe; Cioni, Micaela; Gabbieri, Davide; Zanchettin, Chiara; Agostinelli, Andrea; Mazzaro, Enzo; Gregorio, Omar Di; Gatti, Giuseppe; Faggian, Giuseppe; Filippini, Claudia; Gerosa, Gino

doi:10.1016/j.athoracsur.2013.04.094

Cited by 50 publications

(37 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Some studies suggested an increase in acute mortality following TAVR in patients with significant MR,9 16 18 20 26 but others failed to demonstrate such association 8 17 19. This pooled analysis including patients from TAVR national registries and randomised trials showed that moderate–severe MR was associated with increased 30-day mortality.…”

Section: Discussionmentioning

confidence: 82%

Clinical impact and evolution of mitral regurgitation following transcatheter aortic valve replacement: a meta-analysis

Nombela‐Franco

Eltchaninoff

Zahn

et al. 2015

Heart

Self Cite

132

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 82%

Clinical impact and evolution of mitral regurgitation following transcatheter aortic valve replacement: a meta-analysis

Nombela‐Franco

Eltchaninoff

Zahn

et al. 2015

Heart

Self Cite

132

View full text Add to dashboard Cite

show abstract

“…Thus, we chose a 23‐mm Sapien XT for the aortic valve and a 29 mm for the mitral valve. Because there was a significant discrepancy between the internal diameter of the aortic stented valve and the size of the Sapien valve we found higher postoperative transaortic gradients than a conventional TAVR that is usually around 10 mm Hg . However, this slightly higher gradient doesn't have a significant clinical impact on patient's hemodynamic performance or on functional class.…”

Section: Discussionmentioning

confidence: 76%

Simultaneous transapical aortic and mitral valve‐in‐valve implantation for double prostheses dysfunction: Case report and technical insights

D’Onofrio

Zucchetta

Gerosa

2014

Cathet Cardio Intervent

Self Cite

View full text Add to dashboard Cite

Transcatheter "Valve-in-Valve" implantation (ViV) has shown promising results in high-risk patients suffering from structural valve deterioration (SVD) of a previously implanted heart valve bioprosthesis. We present a case of a 68-year-old woman with a history of three previous cardiac operations on the aortic and mitral valve. At the time of admission she was severely symptomatic due to a simultaneous SVD of a 23 mm aortic and of a 29 mm mitral St. Jude Biocor bioprosthesis. Because of the history of several cardiac operations and to her comorbidities, the patient was considered with an extremely high surgical risk profile and was therefore scheduled for double concomitant mitral and aortic ViV. Through a trans-apical approach, the patient underwent 23 and 29 mm Edwards Sapien XT implantation in the aortic and mitral bioprosthesis, respectively. The procedure was uneventful as well as the following hospital stay. At 6-months follow-up the patient is in NYHA class I. Echocardiography shows that the aortic bioprosthesis has no leak and the mean gradient is 20 mm Hg while the mitral valve has mild leak and maximum and mean gradients are 21 and 10 mm Hg, respectively. The three main technical aspects that should be carefully considered in double concomitant ViV are: sequence of valve deployment (whether to implant the mitral or the aortic valve first), choice of access and valve sizing. In conclusion, double simultaneous trans-apical mitral and aortic ViV is technically feasible. © 2014 Wiley Periodicals, Inc.

show abstract

“…29,[36][37][38] The proportion of patients having TF versus TA varies widely, ranging from 30% to 80% TF, and most clinicians agree that patients undergoing TA are a higher-risk population. Despite this situation, an early report by Bleiziffer and colleagues 40 compared a large series of 153 TF with 50 TA patients who were selected based only on access and reported no difference in 30-day mortality (11.2% TF vs 8.3% TA, P 5 .918) and no stroke in TA versus 7% in TF (P 5 .041).…”

Section: Discussionmentioning

confidence: 99%

Nontransfemoral Approaches to Transcatheter Aortic Valve Replacement

Murdock

Jensen

Thourani

2015

Interventional Cardiology Clinics

View full text Add to dashboard Cite

Medium Term Outcomes of Transapical Aortic Valve Implantation: Results From the Italian Registry of Trans-Apical Aortic Valve Implantation

Cited by 50 publications

References 14 publications

Clinical impact and evolution of mitral regurgitation following transcatheter aortic valve replacement: a meta-analysis

Clinical impact and evolution of mitral regurgitation following transcatheter aortic valve replacement: a meta-analysis

Simultaneous transapical aortic and mitral valve‐in‐valve implantation for double prostheses dysfunction: Case report and technical insights

Nontransfemoral Approaches to Transcatheter Aortic Valve Replacement

Contact Info

Product

Resources

About